PET
9
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke
Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients
Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
Precision Medical Diagnosis for Parkinson's Disease - The Quantitative Analysis System for PET/MRI Images in Patients
PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2